Effects of Saquinavir and Nelfinavir on HIV-1 in the Central Nervous System
Author Information
Author(s): Aylin Yilmaz, Dietmar Fuchs, Lars Hagberg, Ulrika Nillroth, Lars Ståhle, Jan-Olof Svensson, Magnus Gisslén
Primary Institution: Department of Infectious Diseases, The Sahlgrenska Academy, Göteborg University, Göteborg, Sweden
Hypothesis
The study aims to determine the cerebrospinal fluid (CSF) concentrations of saquinavir and nelfinavir and their effects on HIV-1 infection in the CNS.
Conclusion
Saquinavir and nelfinavir, in combination with two NRTIs, decrease the CSF viral load and, to a lesser extent, intrathecal immunoactivation.
Supporting Evidence
- None of the patients had HIV-1 RNA < 50 copies/mL in CSF or plasma before treatment.
- 5 out of 7 patients had HIV-1 RNA < 50 copies/mL in CSF or plasma after treatment.
- Neopterin and β2-microglobulin levels decreased significantly in both CSF and serum.
Takeaway
This study looked at how two HIV drugs work in the brain and found that they can lower the amount of virus in the brain fluid.
Methodology
Paired CSF and plasma samples were collected from 8 HIV-1 infected patients before and after treatment, and various biomarkers were analyzed.
Potential Biases
Potential bias due to the small number of participants and the study being conducted at a single center.
Limitations
The study had a small sample size and was limited to a specific patient population.
Participant Demographics
Eight antiretroviral-naïve HIV-1 infected patients, aged 27 to 59, with a mix of symptomatic and asymptomatic individuals.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website